Tesofensine
Tesofensine is an oral tablet first developed for Parkinson's and Alzheimer's disease, where weight loss turned up as an unexpected finding. It has since been studied in Phase 2 and Phase 3 obesity trials in adults, with about 1,600 patients exposed at therapeutic amounts.
At a glance
- Pharmaceutical
- oral
- Not yet audited here; the reference library calls it emerging
- Sources differ. See the source
How much to draw
Full calculator →The reference does not report a single injectable amount for Tesofensine, so the amount is yours to enter. The arithmetic is the same for any vial. How to reconstitute a vial.
What sources report
These are figures published elsewhere, reproduced with their source. Peppersite does not recommend an amount for Tesofensine or for anything else, and nothing below has been checked against the study it came from.
| Amount | Frequency | Route | Reported by |
|---|---|---|---|
| Standard: 0.5 mg once daily · Low: 0.25 mg once daily | once daily24 weeks · 24 weeks on | Oral tablet | Peptide Dosing ProtocolsWhat it saysHideHalf-life: about 9 days. The standard dosing for tesofensine is 0.5 mg taken once daily. |
- once daily24 weeks · 24 weeks on
- Oral tablet
- Peptide Dosing Protocols
What it saysHide
Half-life: about 9 days. The standard dosing for tesofensine is 0.5 mg taken once daily.
We have not published an audit on Tesofensine. Everything below is reference material, not our own reading of the literature, treat it as a starting point for questions, not as a grade.
How it is thought to work
Tesofensine stops the brain from recycling three signaling chemicals, so more of each stays active in the gap between brain cells. That produces less appetite and a small rise in the calories the body burns at rest, and together these open the gap that pushes weight down. Researchers call it a triple monoamine reuptake inhibitor, blocking the transporters for dopamine, norepinephrine and serotonin, with the appetite effect tied to the hypothalamus and the energy effect to norepinephrine in tissues outside the brain. Its half-life is about 9 days, so levels keep building for roughly 4 to 6 weeks before leveling off, which means the full appetite effect builds gradually and side effects appearing at week 5 or 6 often track that buildup rather than the most recent tablet.
It works in the brain by blocking the reuptake of three signaling chemicals: dopamine, norepinephrine, and serotonin, leading to lower appetite and increased resting energy use. [Source: Peptide Dosing Protocols]
Reported side effects
Seen in studies: the most common effects across trials were dry mouth, nausea, dizziness, abdominal pain, constipation and insomnia, with dry mouth the single most reported symptom. In the Phase 2 study, about 71 percent of patients in the 0.5 mg arm finished the 24 weeks and roughly 20 percent withdrew because of side effects. Heart rate rose by an average of 7.4 beats per minute in the 0.5 mg arm versus placebo, with a 5 to 10 bpm rise described as typical at that amount. Blood pressure did not rise meaningfully at 0.25 mg or 0.5 mg but did at 1.0 mg, which is why that higher amount was dropped from Phase 3 and why US and EU regulators have been reluctant to advance the programme without a dedicated cardiovascular outcomes study. Insomnia, vivid dreams and shorter sleep were reported, along with anxiety, irritability and mood changes, plus headache, dizziness and fatigue less commonly.
Not ruled out: the Phase 2 paper showed no clear depression signal, but a letter in The Lancet noted that the trial excluded people with psychiatric histories, which makes the safety estimate look better than it might be in the general population. Trial results came from manufactured tablets with verified content, and grey-market product carries no such guarantee, with variable tablet content described as a major source of unexpected adverse events.
Who should avoid it
People with uncontrolled high blood pressure or known heart disease: tesofensine raises heart rate, and the 1.0 mg amount raised blood pressure as well.
People with anxiety disorders, bipolar disorder or a history of psychosis: the drug increases monoamine signaling and may worsen these conditions.
People taking MAO inhibitors: the combination raises the risk of serotonin syndrome and severe blood pressure spikes.
People taking SSRIs, SNRIs or other serotonin-raising drugs: the combined load on the serotonin system is a real concern even though no formal interaction study exists.
People taking strong CYP3A4 inhibitors, such as some antifungals, some antibiotics and large amounts of grapefruit juice: these can raise tesofensine levels.
People who are pregnant, planning pregnancy or breastfeeding: tesofensine has not been studied in these groups.
Children and adolescents: obesity trial data cover adults only.
What gets monitored
Resting heart rate and blood pressure at baseline and regular intervals; body weight and waist circumference; mood, sleep, and anxiety screening, especially in the first few weeks; signs of fluid changes; routine labs (glucose, lipids, electrolytes). (reported by Peptide Dosing Protocols)
Common questions
Is tesofensine FDA-approved?
No. As of June 2026 it is not approved by the FDA for any use. It is an investigational drug in the United States and is going through a delayed approval process in Mexico.
What amounts were studied in clinical trials?
The two most studied amounts were 0.25 mg and 0.5 mg, taken once daily as an oral tablet. A 1.0 mg arm in Phase 2 was dropped from Phase 3 after blood pressure rose at that level.
How long does tesofensine take to work?
Some appetite reduction is reported in the first one to two weeks, with most weight loss accumulating after 4 to 6 weeks. That timing matches the drug building up to steady levels in the body.
Why does tesofensine have such a long half-life?
It is broken down slowly, with a half-life of about 9 days, so each daily tablet adds to what is still present from earlier days. Levels keep rising for roughly 4 to 6 weeks before leveling off.
What time of day was tesofensine taken in trials?
Trial protocols asked patients to take the tablet in the morning. The reason given is that it raises norepinephrine and dopamine, which can disrupt sleep, so morning timing kept the strongest signal during the day.
Does tesofensine raise blood pressure or heart rate?
It raises heart rate in a dose-dependent way, by an average of 7.4 beats per minute in the 0.5 mg arm versus placebo. Blood pressure was largely unchanged at 0.25 mg and 0.5 mg but did rise at 1.0 mg.
Can tesofensine be combined with semaglutide or tirzepatide?
No combination trial has been published. Sources note that combining appetite suppressants increases risks.
What is the difference between tesofensine, Tesomet and Nupenta?
Tesofensine is the single active compound on its own. Tesomet includes metoprolol alongside it, and Nupenta is a combination product.
Sources
- 01Astrup A, Madsbad S, Breum L, Jensen TJ, Kroustrup JP, Larsen TM Effect of tesofensine on bodyweight loss, body composition, and quality of life in obese patients: a randomised, double-blind, placebo-controlled trial. The Lancet (2008)
- 02Doggrell SA Tesofensine — a novel potent weight loss medicine. Evaluation of Astrup et al. (Lancet 2008). Expert Opinion on Investigational Drugs (2009)
- 03The Lancet Editors Expression of concern — Effect of tesofensine on bodyweight loss, body composition, and quality of life in obese patients. The Lancet (2014)
- 04Lehr T, Staab A, Tillmann C, et al. Contribution of the active metabolite M1 to the pharmacological activity of tesofensine in vivo: a pharmacokinetic-pharmacodynamic modelling approach. British Journal of Pharmacology (2008)
- 05Appel L, Bergstrom M, Buus Lassen J, Langstrom B Tesofensine, a novel triple monoamine re-uptake inhibitor with anti-obesity effects: dopamine transporter occupancy as measured by PET. European Neuropsychopharmacology (2014)
- 06Saniona AB Saniona's tesofensine meets primary and secondary endpoints in Phase 3 obesity registration trial (Viking study). Saniona corporate press release / Euroland Investor (2018)
- 07Saniona AB Saniona's partner Medix receives favorable opinion for tesofensine for the treatment of obesity in Mexico. Saniona / Nasdaq News (2023)
- 08Saniona AB Mexican application for tesofensine not yet approved — Saniona update. Inderes / Saniona (2024)
- 09Perez CI, Luis-Islas J, Lopez A, et al. Tesofensine, a novel antiobesity drug, silences GABAergic hypothalamic neurons. PLOS ONE (2024)
- 10Onakpoya IJ, Lee JJ, Mahtani KR, Aronson JK, Heneghan CJ Neuropsychiatric adverse effects of centrally acting antiobesity drugs: a systematic review of randomized controlled trials. PMC / Frontiers (2019)
- 11Saniona AB Tesofensine pipeline page. Saniona corporate site (2024)
- 12US Food and Drug Administration Novel Drug Approvals for 2026. FDA.gov (2026)
The reference sections on this page come from a compound library we import, not from our own review of the studies. Our own evidence grade appears only where an audit is linked. Research use only; nothing here is medical advice or a protocol.
5-Amino-1MQ (5-amino-1-methylquinolinium) is a small lab-made molecule, not a true peptide, though it is often sold alongside research peptides. It is studied for shrinking fat cells and raising NAD+ levels, and all evidence so far comes from cell and rodent studies, with no published human trial.
BPC-157 (Body Protection Compound 157) is a lab-made chain of 15 amino acids based on a sequence first found in human gastric juice. It is mostly studied in animal models of tendon, ligament, gut and blood-vessel injury, and human evidence is limited to three small pilots.
Cerluten is an oral peptide bioregulator referenced for nervous system support. Its proposed action, tissue-specific peptide bioregulation, is described as theoretical.
CJC-1295 with DAC is a lab-made 30-amino-acid copy of growth hormone-releasing hormone, altered so it attaches to albumin, a protein in the blood. It was studied in early human trials for its effect on growth hormone and IGF-1 levels.
This is a combination research blend sold as one vial: CJC-1295 without DAC, a copy of growth hormone-releasing hormone, plus Ipamorelin, a short peptide that acts on the ghrelin receptor. It is studied as a GHRH and GHRP pairing in growth-hormone research.
Endoluten is a peptide bioregulator taken by mouth, listed in the reference library as pineal support. Its proposed action, tissue-specific peptide bioregulation, is described as theoretical.